Novavax Reports Fourth Quarter and Year-End 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- US stock index futures slip as high-stakes Iran, inflation tests loom
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
Novavax (NVAX) Weakness Over Increased Spending is Unwarranted - FBR
March 1, 2016 7:22 AM ESTFBR Capital analyst, Vernon Bernardino, reiterated his Outperform rating as vaccine developer Novavax (NASDAQ: NVAX) reported 4Q15 financial results and presented highlights of its 2015 accomplishments: completion of enrollment ahead of guidance for the RSV vaccine Phase III study in elderly adults, completion of enrollment in the Phase II rollover study, and initiation of a second RSV vaccine Phase III study (maternal immunization of infants). The analyst believes... More
Novavax (NVAX) Misses Q4 EPS by 15c
February 29, 2016 7:33 AM ESTNovavax (NASDAQ: NVAX) reported Q4 EPS of ($0.29), $0.15 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $5.9 million versus the consensus estimate of $8.07 million.
2016 Anticipated Events:
Announce top-line data from Resolve, the... More